We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+30.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$358M
Cap. Flow
-$161M
Cap. Flow %
-5.18%
Top 10 Hldgs %
35.61%
Holding
108
New
34
Increased
17
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$63.9M
2
MRK icon
Merck
MRK
+$61.9M
3
CI icon
Cigna
CI
+$60.7M
4
CGON icon
CG Oncology
CGON
+$59.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$53.3M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$81.9M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$65.2M
3
IMGN
Immunogen Inc
IMGN
+$54.2M
4
BHVN icon
Biohaven
BHVN
+$53.1M
5
ZTS icon
Zoetis
ZTS
+$47.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPSC icon
76
Century Therapeutics
IPSC
$364M
$5.11M 0.16%
1,221,555
-133,445
-10% -$565K
KYTX icon
77
Kyverna Therapeutics
KYTX
$430M
$5.03M 0.16%
+202,333
New +$5.65M
EBS icon
78
Emergent Biosolutions
EBS
$379M
$4.83M 0.16%
+1,908,000
New +$4.3M
KZR
79
DELISTED
Kezar Life Sciences
KZR
$4.53M 0.15%
502,600
+55
+0% +$501
BHVN icon
80
Biohaven
BHVN
$2.02B
$4.1M 0.13%
75,000
-1,073,308
-93% -$53.1M
ANTX icon
81
AN2 Therapeutics
ANTX
$181M
$3.74M 0.12%
1,150,000
+10,000
+0.9% +$109K
DNA icon
82
Ginkgo Bioworks
DNA
$498M
$3.48M 0.11%
+75,000
New +$3.88M
XFOR icon
83
X4 Pharmaceuticals
XFOR
$377M
$3.35M 0.11%
+80,433
New +$2.24M
COGT icon
84
Cogent Biosciences
COGT
$6.76B
$3M 0.1%
+445,706
New +$2.76M
PACB icon
85
Pacific Biosciences
PACB
$435M
$2.53M 0.08%
+675,000
New +$3.95M
SCYX icon
86
SCYNEXIS
SCYX
$37.4M
$2.13M 0.07%
181,091
– –
KOD icon
87
Kodiak Sciences
KOD
$2.5B
$1.58M 0.05%
+300,000
New +$1.47M
HYPR icon
88
Hyperfine
HYPR
$88.4M
$1.19M 0.04%
1,188,178
– –
CMAX
89
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$102K ﹤0.01%
21,200
– –
NUVB.WS
90
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$27.1K ﹤0.01%
89,543
– –
A icon
91
Agilent Technologies
A
$39.6B
– –
-99,000
Closed -$13.8M
AKRO
92
DELISTED
Akero Therapeutics
AKRO
– –
-235,000
Closed -$5.49M
AMLX icon
93
Amylyx Pharmaceuticals
AMLX
$2.19B
– –
-64,501
Closed -$949K
ARGX icon
94
argenx
ARGX
$55.2B
– –
-31,000
Closed -$11.8M
ARWR icon
95
Arrowhead Research
ARWR
$12.1B
– –
-714,000
Closed -$21.8M
BDX icon
96
Becton Dickinson
BDX
$46.4B
– –
-165,706
Closed -$40.4M
CI icon
97
CALL
Cigna
CI
$78.4B
– –
-350,000
Closed -$105M
CMPX icon
98
Compass Therapeutics
CMPX
$349M
– –
-1,599,600
Closed -$2.5M
CRNX icon
99
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-529,000
Closed -$18.8M
HUM icon
100
Humana
HUM
$43.9B
– –
-100,000
Closed -$45.8M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2024 Portfolio in Review

As of Q1 2024, Avidity Partners Management held 108 positions worth $3.1B, up 13% from $2.74B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Avidity Partners Management withdrew a net $161M in Q1 2024, closing 18 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $65.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Illumina worth $63.7M.

  • Avidity Partners Management's largest Q1 2024 buy was Illumina: 477,095 shares worth $63.7M.
  • Avidity Partners Management added most to Intuitive Surgical in Q1 2024, an estimated $53.3M increase.
  • Avidity Partners Management's biggest Q1 2024 reduction was Thermo Fisher Scientific, cutting an estimated $81.9M.
  • Avidity Partners Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $65.2M.
  • Avidity Partners Management's ten largest holdings make up 36% of its $3.1B portfolio in Q1 2024.
  • Avidity Partners Management opened 34 new positions and closed 18 in Q1 2024.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $3.1B.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.